Daisuke Nakano Selected Research

Aldosterone

1/2022	Hepatocellular carcinoma induces body mass loss in parallel with osmolyte and water retention in rats.
11/2013	Aldosterone aggravates glucose intolerance induced by high fructose.
10/2012	Aldosterone induces p21-regulated apoptosis via increased synthesis and secretion of tumour necrosis factor-α in human proximal tubular cells.
3/2012	Aldosterone does not contribute to renal p21 expression during the development of angiotensin II-induced hypertension in mice.
2/2012	Aldosterone induces vascular insulin resistance by increasing insulin-like growth factor-1 receptor and hybrid receptor.
2/2011	Aldosterone/Mineralocorticoid receptor stimulation induces cellular senescence in the kidney.
1/2011	Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney.
9/2009	Inhibitory effects of a dihydropyridine calcium channel blocker on renal injury in aldosterone-infused rats.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daisuke Nakano Research Topics

Disease

29	Hypertension (High Blood Pressure) 01/2021 - 09/2002
18	Neoplasms (Cancer) 01/2022 - 05/2010
14	Insulin Resistance 01/2021 - 09/2009
13	Fibrosis (Cirrhosis) 02/2021 - 09/2009
11	Stomach Neoplasms (Stomach Cancer) 01/2022 - 11/2008
10	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022 - 05/2010
9	Hypoxia (Hypoxemia) 06/2021 - 10/2005
9	Albuminuria 01/2020 - 11/2010
8	Obesity 11/2021 - 12/2012
8	Neoplasm Metastasis (Metastasis) 09/2021 - 11/2008
7	Glucose Intolerance 01/2022 - 01/2010
7	Inflammation (Inflammations) 11/2021 - 05/2010
6	Body Weight (Weight, Body) 01/2022 - 07/2010
6	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 12/2021 - 07/2011
6	Diabetic Nephropathies (Diabetic Nephropathy) 01/2019 - 11/2008
5	Hyperglycemia 11/2021 - 07/2016
5	Chronic Renal Insufficiency 06/2021 - 09/2017
5	Anemia 06/2021 - 09/2017
5	Proteinuria 03/2020 - 09/2009
4	Hemorrhage 04/2022 - 01/2018
4	Type 2 Diabetes Mellitus (MODY) 11/2021 - 02/2011
4	Colorectal Neoplasms (Colorectal Cancer) 01/2019 - 11/2009
3	Fistula 04/2022 - 11/2008
3	Wounds and Injuries (Trauma) 01/2022 - 09/2009
3	Dyslipidemias (Dyslipidemia) 01/2022 - 12/2012
3	Reperfusion Injury 01/2021 - 04/2014
3	Ischemia 01/2021 - 04/2014
3	Glycosuria 07/2020 - 06/2018
3	Vascular Remodeling 01/2014 - 10/2011
3	Hypertrophy 02/2012 - 04/2011
3	Carcinoma (Carcinomatosis) 05/2010 - 11/2008
2	Dehydration (Water Stress) 11/2021 - 12/2020
2	Ovarian Neoplasms (Ovarian Cancer) 09/2021 - 01/2017
2	Osteosarcoma (Osteogenic Sarcoma) 09/2021 - 01/2017
2	Kidney Diseases (Kidney Disease) 12/2020 - 07/2016
2	Adenocarcinoma 01/2020 - 03/2015
2	Oliguria 01/2020 - 01/2018

Drug/Important Bio-Agent (IBA)

20	SaltsIBA 01/2022 - 12/2003
18	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2011
12	Angiotensin IIIBA 11/2018 - 09/2009
10	Messenger RNA (mRNA)IBA 11/2021 - 09/2009
9	Proteins (Proteins, Gene)FDA Link 01/2022 - 09/2009
9	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2022 - 04/2012
9	olmesartanIBA 01/2018 - 12/2007
8	AldosteroneIBA 01/2022 - 09/2009
8	SodiumIBA 01/2022 - 01/2013
8	Sodium-Glucose Transporter 2 InhibitorsIBA 11/2021 - 05/2016
8	ReninIBA 01/2020 - 09/2009
8	Insulin (Novolin)FDA Link 01/2020 - 02/2011
6	Angiotensin Receptor AntagonistsIBA 01/2022 - 06/2006
5	Erythropoietin FDA Link 12/2020 - 02/2016
5	Eplerenone (Inspra)FDA LinkGeneric 03/2012 - 09/2009
4	Sulfides (Thioethers)IBA 09/2021 - 01/2012
4	Adenine FDA LinkGeneric 12/2020 - 09/2017
4	Hydralazine (Apresoline)FDA LinkGeneric 03/2020 - 12/2003
4	Prorenin ReceptorIBA 01/2020 - 01/2010
4	Desoxycorticosterone Acetate (DOCA)FDA Link 03/2008 - 12/2003
3	Urea (Carbamide)FDA LinkGeneric 01/2022 - 07/2020
3	Spironolactone (Aldactone)FDA LinkGeneric 01/2022 - 11/2013
3	LignansIBA 12/2021 - 09/2002
3	Blood Glucose (Blood Sugar)IBA 11/2021 - 02/2011
3	Prolyl Hydroxylases (Prolyl Hydroxylase)IBA 06/2021 - 02/2016
3	esaxerenoneIBA 02/2021 - 01/2019
3	CreatinineIBA 12/2020 - 01/2018
3	1,5- anhydro- 1- (5- (4- ethoxybenzyl)- 2- methoxy- 4- methylphenyl)- 1- thioglucitolIBA 07/2020 - 04/2017
3	CateninsIBA 01/2020 - 03/2015
3	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2019 - 02/2012
3	Glucagon-Like Peptide 1 (GLP 1)IBA 10/2018 - 04/2012
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 06/2006
3	AntioxidantsIBA 01/2018 - 10/2011
3	FructoseIBA 11/2013 - 09/2009
3	NADPH Oxidases (NAD(P)H oxidase)IBA 08/2013 - 12/2006
3	sesaminIBA 03/2008 - 09/2002
2	Mineralocorticoid Receptor AntagonistsIBA 01/2022 - 03/2010
2	Pharmaceutical PreparationsIBA 01/2022 - 01/2021
2	Drinking WaterIBA 01/2022 - 09/2009
2	Triglycerides (Triacylglycerol)IBA 01/2022 - 01/2018
2	molidustatIBA 06/2021 - 12/2020
2	NitrogenIBA 12/2020 - 07/2020
2	Valsartan (Vals)FDA Link 03/2020 - 01/2012
2	Peptides (Polypeptides)IBA 01/2020 - 02/2009
2	LipopolysaccharidesIBA 01/2020 - 01/2018
2	Oxidants (Oxidizing Agents)IBA 01/2020 - 01/2018
2	Sodium-Glucose Transport ProteinsIBA 01/2020 - 01/2018
2	Glucagon-Like Peptide-1 ReceptorIBA 01/2020 - 10/2018
2	DesminIBA 01/2019 - 11/2010
2	NPHS2 proteinIBA 01/2019 - 03/2010
2	nephrinIBA 01/2019 - 03/2010
2	Antihypertensive Agents (Antihypertensives)IBA 01/2019 - 12/2003
2	Chymases (Chymase)IBA 11/2018 - 09/2009

Therapy/Procedure

14	Therapeutics 09/2021 - 12/2003
9	Drug Therapy (Chemotherapy) 12/2012 - 11/2008
6	Gastrectomy 12/2020 - 11/2010
4	Oral Administration 06/2018 - 04/2007
3	Neoadjuvant Therapy 11/2010 - 06/2009
2	Surgical Instruments (Clip) 04/2022 - 02/2022
2	Nephrectomy 06/2021 - 01/2021
2	Caloric Restriction 01/2021 - 01/2020
2	Denervation 01/2020 - 03/2012
2	Resuscitation 01/2020 - 12/2015